Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevos inhibidores de fosfolipasa citosólica A2 (cPLA2) estables a la degradación para aplicación sistémica en enfermedades inflamatorias e infecciosas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160202001
Publicado:
16/02/2016
Caducidad:
16/02/2017
Resumen:
Una universidad alemana ha desarrollado nuevos inhibidores de fosfolipasa citosólica A2 (cPLA2) estables a la degradación. Este grupo de sustancias es más estable a la degradación y ofrece una nueva clase de inhibidores de cPLA2 para la aplicación sistémica en enfermedades inflamatorias e infecciosas y otros trastornos inmunológicos. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de licencia para el uso comercial y continuar con la investigación y desarrollo, por ejemplo, en el campo de inmunología.

Details

Tittle:
Novel degradation-stable inhibitors of the cytosolic phospholipase A2 (cPLA2) for systemic application in inflammatory and infectious diseases
Summary:
A German university has developed a novel degradation-stable inhibitors of the cytosolic phospholipase A2 (cPLA2). The herewith offered group of substances is more degradation stable and thus displays a novel class of cPLA2 inhibitors for systemic application in inflammatory and infectious diseases as well as other immunological disorders. The German University offers license agreements for commercial use to pharmaceutical industry as well as the opportunity for further research co-development.
Description:
The cytosolic phospholipase A2 (cPLA2) is an enzyme that generates arachidonic acid by the cleavage of membrane phospholipids in response to stimuli like bacterial lipopolysaccharides. Arachidonic acid in turn is the precursor of the inflammatory mediator families of leukotrienes, prostaglandins and thromboxanes. Thus, the cPLA2 is strongly involved in inflammatory reactions, and cPLA2-deficient mice accordingly show reduced inflammatory, allergic and anaphylactic reactions as well as reduced infarction and neurologic deficits after experimental stroke. Previously developed inhibitors of the cPLA2 had the disadvantage of fast metabolic degradation, which only allowed topic application.

A German university herby offers a group of substances that is more degradation-stable and thus displays a novel class of cPLA2 inhibitors for systemic application in inflammatory and infectious diseases as well as other immunological disorders.

The German University offers license agreements for commercial use to pharmaceutical companies as well as the opportunity for further research co-development. e.g. in the field of immunology.
Advantages and Innovations:
- Degradation-stable cPLA2 inhibitors
- novel class of substances for systemic treatment of infectious and inflammatory disorders
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applied for at European Patent Office

Partner sought

Type and Role of Partner Sought:
The German university offers license agreements and the opportunity for further research co-development.
The invented substances are of high interest for any pharmaceutical company with an immunological pipeline and may constitute the first-in-class cPLA2 inhibitors for systemic application.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos